A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity
Dendritic cell- (DC-) based vaccination has emerged as a promising antitumour immunotherapy. However, overcoming immune tolerance and immunosuppression in the tumour microenvironment (TME) is still a great challenge. Recent studies have shown that Rose Bengal (RB) can effectively induce immunogenic...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2022/1178874 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567739971010560 |
|---|---|
| author | Lanlin Zhang Jiangyuan Du Qian Song Chufan Zhang Xianghua Wu |
| author_facet | Lanlin Zhang Jiangyuan Du Qian Song Chufan Zhang Xianghua Wu |
| author_sort | Lanlin Zhang |
| collection | DOAJ |
| description | Dendritic cell- (DC-) based vaccination has emerged as a promising antitumour immunotherapy. However, overcoming immune tolerance and immunosuppression in the tumour microenvironment (TME) is still a great challenge. Recent studies have shown that Rose Bengal (RB) can effectively induce immunogenic cell death (ICD) in cancer cells, presenting whole tumour antigens for DC processing and presentation. However, the synergistic antitumour effect of combining intralesional RB with immature DCs (RB-iDCs) remains unclear. In the present study, we investigated whether RB-iDCs have superior antitumour effects compared with either single agent and evaluated the immunological mechanism of RB-iDCs in a murine lung cancer model. The results showed that intralesional RB-iDCs suppressed subcutaneous tumour growth and lung metastasis, which resulted in 100% mouse survival and significantly increased TNF-α production by CD8+ T cells. These effects were closely related to the induction of the expression of distinct ICD hallmarks by RB in both bulk cancer cells and cancer stem cells (CSCs), especially calreticulin (CRT), thus enhancing immune effector cell (i.e., CD4+, CD8+, and memory T cells) infiltration and attenuating the accumulation of immunosuppressive cells (i.e., Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs)) in the TME. This study reveals that the RB-iDC vaccine can synergistically destroy the primary tumour, inhibit distant metastasis, and prevent tumour relapse in a lung cancer mouse model, which provides important preclinical data for the development of a novel combinatorial immunotherapy. |
| format | Article |
| id | doaj-art-89b8fcf9590f438988fb5e55a96d5c0c |
| institution | Kabale University |
| issn | 2314-7156 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-89b8fcf9590f438988fb5e55a96d5c0c2025-02-03T01:00:46ZengWileyJournal of Immunology Research2314-71562022-01-01202210.1155/2022/1178874A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour ImmunityLanlin Zhang0Jiangyuan Du1Qian Song2Chufan Zhang3Xianghua Wu4Department of Medical OncologyShanghai TCM-Integrated Institute of Vascular AnomaliesDepartment of Medical OncologyDepartment of Medical OncologyDepartment of Medical OncologyDendritic cell- (DC-) based vaccination has emerged as a promising antitumour immunotherapy. However, overcoming immune tolerance and immunosuppression in the tumour microenvironment (TME) is still a great challenge. Recent studies have shown that Rose Bengal (RB) can effectively induce immunogenic cell death (ICD) in cancer cells, presenting whole tumour antigens for DC processing and presentation. However, the synergistic antitumour effect of combining intralesional RB with immature DCs (RB-iDCs) remains unclear. In the present study, we investigated whether RB-iDCs have superior antitumour effects compared with either single agent and evaluated the immunological mechanism of RB-iDCs in a murine lung cancer model. The results showed that intralesional RB-iDCs suppressed subcutaneous tumour growth and lung metastasis, which resulted in 100% mouse survival and significantly increased TNF-α production by CD8+ T cells. These effects were closely related to the induction of the expression of distinct ICD hallmarks by RB in both bulk cancer cells and cancer stem cells (CSCs), especially calreticulin (CRT), thus enhancing immune effector cell (i.e., CD4+, CD8+, and memory T cells) infiltration and attenuating the accumulation of immunosuppressive cells (i.e., Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs)) in the TME. This study reveals that the RB-iDC vaccine can synergistically destroy the primary tumour, inhibit distant metastasis, and prevent tumour relapse in a lung cancer mouse model, which provides important preclinical data for the development of a novel combinatorial immunotherapy.http://dx.doi.org/10.1155/2022/1178874 |
| spellingShingle | Lanlin Zhang Jiangyuan Du Qian Song Chufan Zhang Xianghua Wu A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity Journal of Immunology Research |
| title | A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity |
| title_full | A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity |
| title_fullStr | A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity |
| title_full_unstemmed | A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity |
| title_short | A Novel In Situ Dendritic Cell Vaccine Triggered by Rose Bengal Enhances Adaptive Antitumour Immunity |
| title_sort | novel in situ dendritic cell vaccine triggered by rose bengal enhances adaptive antitumour immunity |
| url | http://dx.doi.org/10.1155/2022/1178874 |
| work_keys_str_mv | AT lanlinzhang anovelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT jiangyuandu anovelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT qiansong anovelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT chufanzhang anovelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT xianghuawu anovelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT lanlinzhang novelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT jiangyuandu novelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT qiansong novelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT chufanzhang novelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity AT xianghuawu novelinsitudendriticcellvaccinetriggeredbyrosebengalenhancesadaptiveantitumourimmunity |